Answers are grounded in this paper and cite their sources.
Demonstrates safety implications of GLP-1 medication use in obesity, suggesting the need for oversight.
Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care.
No takes yet. Share an insight, caveat, or question.
Chao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: